The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response

被引:46
|
作者
Luo, Min [1 ]
Fu, Liwu [1 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangdong Esophageal Canc Inst,Canc Ctr, Guangzhou 510275, Guangdong, Peoples R China
关键词
programmed cell death 1; programmed cell death 1 ligand; chemotherapy; immunotherapy; REGULATORY T-CELLS; PD-L1 SURFACE EXPRESSION; BREAST-CANCER CELLS; B7-H1; EXPRESSION; ANTI-PD-L1; ANTIBODY; PDL1; UP-REGULATION; RESTORES T; BLOCKADE; SAFETY;
D O I
10.18632/oncotarget.7631
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Most tumors are immunogenic which would trigger some immune response. Chemotherapy also has immune potentiating mechanisms of action. But it is unknown whether the immune response is associated with the efficacy of chemotherapy and the development of chemoresistance. Recently, there is a growing interest in immunotherapy, among which the co-inhibitory molecules, programmed cell death 1/programmed cell death 1 ligand (PD-1/PD-L1) leads to immune evasion. Since some reports showed that conventional chemotherapeutics can induce the expression of PD-L1, we try to summarize the effect of chemotherapy on PD-1/PD-L1 axis and some potential molecules relevant to PD-1/PD-L1 in chemoresistance in this review.
引用
收藏
页码:29794 / 29803
页数:10
相关论文
共 50 条
  • [31] New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone
    Hu-Lieskovan, Siwen
    Ribas, Antoni
    CANCER JOURNAL, 2017, 23 (01) : 10 - 22
  • [32] Tumor Progression by Immune Evasion in Melanoma Role of the Programmed Cell Death-1/Programmed Cell Death-1 Ligand 1 Interaction
    Kashani-Sabet, Mohammed
    CANCER, 2010, 116 (07) : 1623 - 1625
  • [33] Programmed death-ligand 1 expression in the immune compartment of colon carcinoma
    Yilmaz, Osman
    Pankaj, Amaya
    Neyez, Azfar
    Rickelt, Steffen
    Taylor, Martin
    Lang, Evan R.
    Leijsen, Lieve
    Dinaux, Anne
    Shroff, Stuti G.
    Crotty, Rory
    Zhang, M. Lisa
    Cerda, Sandra
    Zhao, Qing
    Ferrone, Cristina
    Ting, David T.
    Patil, Deepa T.
    Yilmaz, Omer
    Berger, David
    Deshpande, Vikram
    MODERN PATHOLOGY, 2022, 35 (11) : 1740 - 1748
  • [34] Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma
    Todoroki, Keita
    Abe, Yushi
    Matsuo, Katsuhisa
    Nomura, Hidetoshi
    Kawahara, Akihiko
    Nakamura, Yoshiaki
    Nakamura, Moriyoshi
    Seki, Naoko
    Kusukawa, Jingo
    ONCOLOGY LETTERS, 2024, 27 (02)
  • [35] Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix
    Liu, Rongyu
    He, Xinlin
    Li, Zhengyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
    Wang, Tianyu
    Wu, Xiaoxing
    Guo, Changying
    Zhang, Kuojun
    Xu, Jinyi
    Li, Zheng
    Jiang, Sheng
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (04) : 1715 - 1730
  • [37] Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma
    Lee, Kyu Sang
    Lee, Kyoungyul
    Yun, Sumi
    Moon, Seyoung
    Park, Yujun
    Han, Jung Ho
    Kim, Chae-Yong
    Lee, Hye Seung
    Choe, Gheeyoung
    JOURNAL OF NEURO-ONCOLOGY, 2018, 136 (03) : 453 - 461
  • [38] Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
    Huynh, Tiffany G.
    Morales-Oyarvide, Vicente
    Campo, Meghan J.
    Gainor, Justin F.
    Bozkurtlar, Emine
    Uruga, Hironori
    Zhao, Ling
    Gomez-Caraballo, Maria
    Hata, Aaron N.
    Mark, Eugene J.
    Lanuti, Michael
    Engelman, Jeffrey A.
    Mino-Kenudson, Mad
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : 1869 - 1878
  • [39] Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
    Chen, Kaiyan
    Cheng, Guoping
    Zhang, Fanrong
    Zhang, Nan
    Li, Dan
    Jin, Jiaoyue
    Wu, Junzhou
    Ying, Lisha
    Mao, Weimin
    Su, Dan
    ONCOTARGET, 2016, 7 (21) : 30772 - 30780
  • [40] Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer
    Sun, Jin
    Qiu, Miao-Zhen
    Mei, Ting
    Gao, Yuan
    Chang, Boyang
    Zhang, Yuxin
    Wang, Feng-Hua
    Li, Su
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2434 - 2448